Therapeutic Intervention of Eriocitrin in the Reduction of Hyperglycemia in Pre-diabetic Individuals

Pre Diabetes Clinical Trial

Official title:

Therapeutic Intervention of Eriocitrin in Reducing Hyperglycemia in Pre-diabetic Subjects: Double-blind, Randomized, Placebo-controlled Crossover Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03928249
• Other study ID #: SaoPSU12
• Status: Completed
• Phase: N/A
• Start date: December 1, 2019
• Est. completion date: October 22, 2020

Study information

• Verified date: October 2020
• Source: São Paulo State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Supplementation with citrus bioflavonoids (hesperidin, naringin, diosmin and eriocitrin, among others) has been associated with an improvement in the glycidic and lipid profile, reduction of insulin resistance and systemic inflammation, and reduction of endothelial damage. This study aims to evaluate the effects of eriocitrin supplementation on the metabolic parameters of pre-diabetic individuals. Participants will be adults with pre-diabetes who will receive 200 mg / d of eriocitrin. Before, during and after treatment, anthropometric measures (weight, body composition and circumferences), biochemical (lipid and glucose profile, inflammatory parameters, endothelial markers, liver function, renal function) will be evaluated. Metabolic parameters that constitute risk factors for diabetes and associated chronic diseases are expected to be improved by supplementation with eriocitrin.

Description:

Individuals aged 35-60 years and who present at least one of the following criteria: (1) increased fasting blood glucose from 6.1 to 7.0 mmol / L, (2) decreased glucose tolerance of 7 , 8 to 11.1 mmol / L, and (3) glycated hemoglobin with values between 5.7 and 6.4% 10 will be eligible to participate in this study. The exclusion criteria will be to use hypoglycemic, hypolipidemic drugs, dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds), exercise intensely (more than 10 hours per week), history of cardiovascular diseases , diabetes mellitus, liver and kidney disease. The selected individuals will be distributed randomly in 2 groups through random number generator program. Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, with washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks; group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks. The primary endpoint will be fasting blood glucose, blood glucose 2 hours after oral glucose tolerance test (GTTO), and HbA1c. The secondary endpoint will be insulin, HOMA-IR, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, ALP, yGT, AST, ALT, TNF-α, IL-6, CRP, body weight, body mass index BMI), muscle mass, fat mass, body fat and waist-hip ratio, and macronutrient intake.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: October 22, 2020
• Est. primary completion date: June 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 60 Years

Eligibility

Inclusion Criteria:

• 35-60 years
• Increased fasting blood glucose from 6.1 to 7.0 mmol / L or,
• Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or,
• Glycated hemoglobin with values between 5.7 and 6.4%

Exclusion Criteria:

• Use hypoglycemic, hypolipidemic drugs,
• Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds),
• Exercise intensely (more than 10 hours per week)
• History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.

Related Conditions & MeSH terms

• Glucose Intolerance
• Hyperglycemia
• Pre Diabetes
• Prediabetic State

Intervention

Dietary Supplement:
• Eriocitrin
A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed. Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara) At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.

Locations

Country	Name	City	State
Brazil	Sao Paulo State University "Julio de Mesquita Filho"	Araraquara	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
São Paulo State University

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fasting glycemia	Changes in serum glycemia concentration before and after administration of the intervention/placebo	0-12-18-26 week
Secondary	Rate of change in plasma glucose concentration	Changes in serum 2 hours after oral glucose tolerance test (mg/dL) before and after administration of the intervention / placebo	0-12-18-26 week
Secondary	Rate of change in plasma HbA1c	Changes in serum HbA1c (%) before and after administration of the intervention / placebo	0-12-18-26 week
Secondary	Rate of change in plasma insulin concentration	Changes in serum insulin (µU/mL) before and after administration of the intervention / placebo	0-12-18-26 week
Secondary	Rate of change in plasma lipid concentration	Changes in serum cholesterol (mg/dL), triglycerides (mg/dL),HDL-C(mg/dL), LDL-C(mg/dL) before and after administration of the intervention/placebo	0-12-18-26 week
Secondary	Rate of change in plasma hepatic enzymes	Changes in ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L) before and after administration of the intervention / placebo	0-12-18-26 week
Secondary	Rate of change in plasma inflammatory parameters	Changes in CRP (mg/dL), TNF-a (mg/dL), IL-6 (mg/dL) before and after administration of the intervention / placebo	0-12-18-26 week
Secondary	Rate of change in anthropometric parameters	Changes in body weight (Kg), muscle mass (Kg), fat mass (Kg) before and after administration of the intervention / placebo	0-12-18-26 week